Komal Jhaveri, MD, FACP, discusses the implications of investigating treatment with RLY-2608 in patients with PIK3CA-mutant advanced ER+ breast cancer.
ADCs are rapidly changing the treatment landscape for patients with metastatic breast cancer, with the agents demonstrating improved efficacy and manageable risks.
Dato-DXd May Be Better Tolerated Than Chemo in HR+/HER2– Breast Cancer curetoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from curetoday.com Daily Mail and Mail on Sunday newspapers.
Komal Jhaveri, MD, FACP, discusses the rationale for investigating lasofoxifene alongside abemaciclib in ESR1-mutated estrogen receptor–positive, HER2-negative metastatic breast cancer.